Admedus finalises license and associated milestone payment with 4C Medical

Admedus has announced the complete transfer of its sterilisation method as part of its Adapt tissue treatment process to 4C Medical. As per the Admedus supply agreement with 4C Medical, 4C Medical will pay an additional $US1 Million ($US 0.44M previously received) to use the technology to sterilise the Adapt tissue incorporated in its transcatheter [...]

2020-02-05T12:30:37+00:00February 5th, 2020|Tags: , , , |

Admedus sells distribution rights of CardioCel and Vascucel to focus on TAVI programme

CardioCel Admedus has sold its CardioCel and VascuCel patch business to US-based LeMaitre Vascular for up to $A36.2M ($A22.8M upfront) in cash payments. A press release reports that these products originated from the Admedus’s proprietary, regenerative bioscaffold platform technology and are used to address multiple cardiovascular procedures and repairs. The company’s CEO, [...]

2019-10-15T13:50:18+00:00October 15th, 2019|Tags: , , |
Go to Top